Administered in conjunction with an oral antidepressant

SPRAVATO® demonstrated efficacy in adults with TRD and MDSI1


TRD: Short-term + long-term studies1,2

Efficacy data


MDSI: Short-term studies1

Efficacy data


not require daily dosing

SPRAVATO® should be administered in conjunction with an oral antidepressant1

Learn more

access banner

Once a decision has been made to prescribe SPRAVATO®

SPRAVATO withMe can help navigate access and affordability processes efficiently so you can focus on your patients

Learn more

SPRAVATO withMe is limited to education for patients about SPRAVATO®, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient’s doctor or nurse, or provide case management services.

Next: What makes SPRAVATO® different?

Learn more


1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.

2. Zaki N, Fu DJ, Daly E, et al. Long-term efficacy of esketamine nasal spray in adults with treatment-resistant depression: a subgroup analysis of the ongoing SUSTAIN-3 study. Poster presented at: Neuroscience Education Institute (NEI) Congress; November 4-7, 2021; Colorado Springs, CO.